Relevant bibliographies by topics / Authorized generics / Journal articles
To see the other types of publications on this topic, follow the link: Authorized generics.

Journal articles on the topic 'Authorized generics'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Authorized generics.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Glass, Gregory. "Authorized Generics." Nature Reviews Drug Discovery 4, no. 12 (2005): 953–55. http://dx.doi.org/10.1038/nrd1906.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Patel, JS, DR Baheti, and MP Wagh. "Authorized generics practice." Systematic Reviews in Pharmacy 1, no. 1 (2010): 106. http://dx.doi.org/10.4103/0975-8453.59520.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Moon, J., J. Nkurunziza, A. Jambi, E. Seoane-Vazquez, J. Qian, and R. A. Hansen. "Generic competition and Authorized Generics in the United States." Value in Health 18, no. 3 (2015): A92. http://dx.doi.org/10.1016/j.jval.2015.03.540.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kunst, Manuel, and Ulrike Kaufmann. "Authorized Generics and Biosimilars as Part of Drug Life Cycle Management." GRUR International 69, no. 11 (2020): 1105–12. http://dx.doi.org/10.1093/grurint/ikaa116.

Full text
Abstract:
Abstract Nowadays there is no longer a clear distinction between innovative pharmaceutical companies and generic and biosimilar manufacturers. The latter seek patent protection for new formulations or medical uses of known pharmaceuticals, and originators have responded by building their own generic divisions. Through them, innovative pharmaceutical companies are able to launch their own generics or biosimilars to cushion the loss of revenues after the expiry of blockbuster patents. In particular, in recent years so-called authorized generics and biosimilars have received increased attention a
APA, Harvard, Vancouver, ISO, and other styles
5

McGee, Shelley-Ann Marion. "The economic and pricing impact of authorized generic medicines in South Africa." International Journal of Pharmaceutical and Healthcare Marketing 9, no. 1 (2015): 20–35. http://dx.doi.org/10.1108/ijphm-11-2013-0059.

Full text
Abstract:
Purpose – This paper aims to examine whether authorized generics (AGs) have influenced prices and market shares in markets for molecules facing generic competition in South Africa. AGs (clones), which are identical to the originator brands, offer a solution for originator companies to protect their markets from independent generic (IG) competition. IG competitors have claimed that AGs have a negative impact on pricing and competition. Design/methodology/approach – In a retrospective analysis, pricing and quantity data for 24 months post generic entry were extracted for oral solid dosage form p
APA, Harvard, Vancouver, ISO, and other styles
6

Gagne, Joshua J., Ameet Sarpatwari, and Rishi J. Desai. "Role of Authorized Generics in Postapproval Surveillance of Generic Drug Products." Clinical Pharmacology & Therapeutics 105, no. 2 (2018): 313–15. http://dx.doi.org/10.1002/cpt.1283.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Moran, Donald W., Steven M. Lieberman, and Kara L. Suter. "Banning Authorized Generics Equals Higher Federal Spending." Health Affairs 27, no. 1 (2008): 302–3. http://dx.doi.org/10.1377/hlthaff.27.1.302-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Jones, Gregory H., Michael A. Carrier, Richard T. Silver, and Hagop Kantarjian. "Strategies that delay or prevent the timely availability of affordable generic drugs in the United States." Blood 127, no. 11 (2016): 1398–402. http://dx.doi.org/10.1182/blood-2015-11-680058.

Full text
Abstract:
Abstract High cancer drug prices are influenced by the availability of generic cancer drugs in a timely manner. Several strategies have been used to delay the availability of affordable generic drugs into the United States and world markets. These include reverse payment or pay-for-delay patent settlements, authorized generics, product hopping, lobbying against cross-border drug importation, buying out the competition, and others. In this forum, we detail these strategies and how they can be prevented.
APA, Harvard, Vancouver, ISO, and other styles
9

Shcherbakova, Natalia, Marvin Shepherd, Kenneth Lawson, and Kristin Richards. "The Role of authorized generics in the prescription drug marketplace." Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 8, no. 1 (2011): 28–40. http://dx.doi.org/10.1057/jgm.2011.6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shcherbakova, N., M. Shepherd, K. Lawson, and K. Richards. "PHP98 THE ROLE OF AUTHORIZED GENERICS IN THE PRESCRIPTION DRUG MARKETPLACE." Value in Health 13, no. 3 (2010): A100. http://dx.doi.org/10.1016/s1098-3015(10)72478-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Dusetzina, Stacie B., Nancy L. Keating, and Haiden A. Huskamp. "Authorized Generics and Their Evolving Role in Prescription Drug Pricing and Access." JAMA Internal Medicine 181, no. 4 (2021): 423. http://dx.doi.org/10.1001/jamainternmed.2020.8450.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Bokhari, Farasat A. S., Franco Mariuzzo, and Arnold Polanski. "Entry limiting agreements: First‐mover advantage, authorized generics, and pay‐for‐delay deals." Journal of Economics & Management Strategy 29, no. 3 (2020): 516–42. http://dx.doi.org/10.1111/jems.12351.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Chao, Chon Kit, Hao Hu, Liming Zhang, and Jihong Wu. "Managing the challenges of pharmaceutical patent expiry: a case study of Lipitor." Journal of Science and Technology Policy Management 7, no. 3 (2016): 258–72. http://dx.doi.org/10.1108/jstpm-12-2015-0040.

Full text
Abstract:
Purpose The paper aims to study how global pharmaceutical companies such as Pfizer have managed the challenges of pharmaceutical patent expiry. Design/methodology/approach A case study method was applied. The best-selling brand drug over the past 10 years – Lipitor – was chosen as the case target. Findings For dealing with this, this paper describes all the details of the corresponding strategies of Pfizer before and after patent expiration of Lipitor. Before patent expiry, Pfizer undertook the activities of direct-to-consumer marketing, pricing strategy for competition, legal delay and me-too
APA, Harvard, Vancouver, ISO, and other styles
14

Gulsen Oner, Z., and James E. Polli. "Authorized Generic Drugs: an Overview." AAPS PharmSciTech 19, no. 6 (2018): 2450–58. http://dx.doi.org/10.1208/s12249-018-1073-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Prada, Mariangela, Matteo Ruggeri, Carmen Sansone, Dalila De Fazio, Alessia Tettamanti, and Matteo Mantovani. "Timeline of Authorization and Reimbursement for Oncology Drugs in Italy in the Last 3 Years." Medicine Access @ Point of Care 1 (January 2017): maapoc.0000007. http://dx.doi.org/10.5301/maapoc.0000007.

Full text
Abstract:
Introduction The main purpose of this analysis was to quantify the time elapsed between the validation date of European Medicines Agency (EMA) centralized procedure and the first purchase of a product by at least 1 Italian health care structure, evaluating different variables that affect the process, the number of products approved by the Committee for Medicinal Products for Human Use (CHMP) that are available on the Italian market (July 2016), and the impact of the Cnn class for oncology drugs in Italy. Methods A panel of oncology products has been defined, which considered drugs approved by
APA, Harvard, Vancouver, ISO, and other styles
16

Rein, Frederick H., and Amanda H. Kessel. "Teva v Crawford: Authorising ‘authorised generics’?" Journal of Generic Medicines 3, no. 1 (2005): 62–69. http://dx.doi.org/10.1057/palgrave.jgm.4940099.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Hansen, Richard A., Jingjing Qian, Richard Berg, et al. "Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37, no. 4 (2017): 429–37. http://dx.doi.org/10.1002/phar.1908.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Berndt, Ernst R., Richard Mortimer, Ashoke Bhattacharjya, Andrew Parece, and Edward Tuttle. "Authorized Generic Drugs, Price Competition, And Consumers’ Welfare." Health Affairs 26, no. 3 (2007): 790–99. http://dx.doi.org/10.1377/hlthaff.26.3.790.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Appelt, Silvia. "Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry." Review of Economics and Statistics 97, no. 3 (2015): 654–66. http://dx.doi.org/10.1162/rest_a_00488.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

&NA;. "Authorised generic pharmaceuticals reduce the price and increase the availability of generic medicines,." Inpharma Weekly &NA;, no. 1588 (2007): 3. http://dx.doi.org/10.2165/00128413-200715880-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Alatawi, Y., Md M. Rahman, N. Cheng, et al. "Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications." Journal of Clinical Pharmacy and Therapeutics 43, no. 3 (2017): 327–35. http://dx.doi.org/10.1111/jcpt.12646.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Rein, Frederick H., and Amanda M. Kessel. "Mylan v FDA: Another court decision in favour of ‘authorised generics’." Journal of Generic Medicines 4, no. 1 (2006): 46–52. http://dx.doi.org/10.1057/palgrave.jgm.4950043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Hernandez, Inmaculada, William H. Shrank, Chester B. Good, and Walid F. Gellad. "Savings from the EpiPen Authorized Generic: a Retrospective Analysis of Medicaid Data." Journal of General Internal Medicine 34, no. 9 (2019): 1682–84. http://dx.doi.org/10.1007/s11606-019-04989-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Farrell, Joseph, David J. Balan, Keith Brand, and Brett W. Wendling. "Economics at the FTC: Hospital Mergers, Authorized Generic Drugs, and Consumer Credit Markets." Review of Industrial Organization 39, no. 4 (2011): 271–96. http://dx.doi.org/10.1007/s11151-011-9320-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Class, Selena. "Whither Generics? Why Major Restructuring Lies Ahead." Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 2, no. 3 (2005): 232–39. http://dx.doi.org/10.1057/palgrave.jgm.4940074.

Full text
Abstract:
Generics manufacturers have undergone some of the fastest growth in the pharmaceutical sector in recent years, but can their impressive growth rate be maintained post-2006–2007, when a number of blockbusters are due to lose exclusivity? Some of their major long-term challenges include the dearth of new blockbusters as branded pharma's pipeline dwindles; aggressive defence tactics — such as the development of combination products and over-the-counter switching; authorised generics deals; the lack of an established approval path for biogenerics; and increasing competition from manufacturers in d
APA, Harvard, Vancouver, ISO, and other styles
26

González, Claudia Patricia Vacca, James F. Fitzgerald, and Joan Rovira. "Generics in Latin America: Trends and Regulation." Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 6, no. 1 (2008): 43–56. http://dx.doi.org/10.1057/jgm.2008.32.

Full text
Abstract:
The purpose of this study was to establish regulatory trends related to competing drugs in several Latin American and Caribbean countries and to review regulations and national policies on generic drugs in these countries. Furthermore, information on the incentives to register and produce competing drugs, the promotion of international non-proprietary name (INN) use, the regulation of bioequivalence studies and the substitution of drugs prescribed by lower price alternatives to the public was also obtained. The results showed three regulatory categories: those countries that favour financing o
APA, Harvard, Vancouver, ISO, and other styles
27

Karasawa, Yusuke, Isao Kamae, Kazutaka Nozawa, et al. "Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan." PLOS ONE 16, no. 7 (2021): e0253547. http://dx.doi.org/10.1371/journal.pone.0253547.

Full text
Abstract:
Objectives The aim of this study was to examine the cost-effectiveness of branded and authorized generic (AG) celecoxib for chronic pain patients with osteoarthritis (OA), rheumatoid arthritis (RA), and low back pain (LBP), using real-world cost information for loxoprofen and pharmacotherapy for gastrointestinal bleeding. Methods This cost-effectiveness analysis was performed as a long-term simulation using the Markov model from the Japanese public healthcare payer’s perspective. The analysis was conducted using loxoprofen with real-world weighted price by branded/generic distribution (hereina
APA, Harvard, Vancouver, ISO, and other styles
28

Peny, Jean-Michel, and Jean-Pierre Covilard. "What is the value of authorised generic agreements? Assessments on the French market." Journal of Generic Medicines 4, no. 2 (2006): 106–16. http://dx.doi.org/10.1057/palgrave.jgm.4950061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Cheng, Ning, Tannista Banerjee, Jingjing Qian, and Richard A. Hansen. "Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011." Journal of the American Pharmacists Association 57, no. 3 (2017): 341–48. http://dx.doi.org/10.1016/j.japh.2017.02.014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Hansen, RA, J. Qian, RL Berg, et al. "Comparison of Outcomes Following a Switch From a Brand to an Authorized Versus Independent Generic Drug." Clinical Pharmacology & Therapeutics 103, no. 2 (2017): 310–17. http://dx.doi.org/10.1002/cpt.591.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Cohen, D., J. Crampton, A. Gagarin, G. Gutin, and M. Jones. "Iterative Plan Construction for the Workflow Satisfiability Problem." Journal of Artificial Intelligence Research 51 (November 21, 2014): 555–77. http://dx.doi.org/10.1613/jair.4435.

Full text
Abstract:
The Workflow Satisfiability Problem (WSP) is a problem of practical interest that arises whenever tasks need to be performed by authorized users, subject to constraints defined by business rules. We are required to decide whether there exists a plan - an assignment of tasks to authorized users - such that all constraints are satisfied. It is natural to see the WSP as a subclass of the Constraint Satisfaction Problem (CSP) in which the variables are tasks and the domain is the set of users. What makes the WSP distinctive is that the number of tasks is usually very small compared to the number o
APA, Harvard, Vancouver, ISO, and other styles
32

Carrasco-Portugal, Miriam del Carmen, and Francisco Javier Flores-Murrieta. "Alternativas farmacéuticas: ¿pueden ser intercambiables?" Latin american journal of clinical sciences and medical technology 2, no. 2 (2020): 38–42. http://dx.doi.org/10.34141/ljcs4648190.

Full text
Abstract:
Pharmaceutical alternatives are products with the same active moiety, but different salt, ester or pharmaceutical form. Regulatory agencies have different criteria for this kind of drug. The European Medicines Agency (EMA) accepts the generic substitution using these alternatives, whereas the Food and Drug Administration (FDA) only authorizes generic substitution of pharmaceutical equivalents. The objective of this paper is to describe some relevant aspects that should be considered before deciding on making a generic substitution with pharmaceutical alternatives. It is important to note that
APA, Harvard, Vancouver, ISO, and other styles
33

Taher, Muhammad, Siti Syazwani Shaari, and Deny Susanti. ""Biosimilar" generic version of biologic products?" Current Research on Biosciences and Biotechnology 2, no. 2 (2021): 114–20. http://dx.doi.org/10.5614/crbb.2021.2.2/vdxd7316.

Full text
Abstract:
Biosimilars are currently popular after the expiry date of patents for biological reference products have expired or soon will expire. Besides, this ‘copycat’ version of biologic products offers much lower costs as compared to the reference products, thus promoting better patient access to the treatment of certain diseases such as cancer, inflammatory diseases, skin disorders, and diabetes. This review aims to determine the differences between biosimilars and generic drugs and highlight some issues related to biosimilar products such as comparability, interchangeability, immunogenicity, extrap
APA, Harvard, Vancouver, ISO, and other styles
34

Yang, Shao-yun. "Letting the Troops Loose: Pillage, Massacres, and Enslavement in Early Tang Warfare." Journal of Chinese Military History 6, no. 1 (2017): 1–52. http://dx.doi.org/10.1163/22127453-12341307.

Full text
Abstract:
By analyzing examples ranging from the Sui-Tang transition to the An Lushan Rebellion, I argue that in a practice known as “letting the troops loose,” Tang generals frequently rewarded their officers and soldiers (and themselves) for a victory with the freedom to seize the wives, children, and property of the defeated with impunity, and to kill any who resisted. Attempts to censure or prosecute the generals responsible were rare and usually overruled, because military morale was seen as a higher priority than discipline or humaneness. Tang generals were also authorized to massacre surrendered
APA, Harvard, Vancouver, ISO, and other styles
35

Pazdan, Jadwiga. "UMOCOWANIE DO ZAWARCIA UMOWY O ARBITRAŻ." Zeszyty Prawnicze 3, no. 2 (2017): 299. http://dx.doi.org/10.21697/zp.2003.3.2.13.

Full text
Abstract:
Power to Conclude an Arbitration Agreement on Behalf of Another PersonSummaryThe legal character of an arbitration agreement is disputable in the Polish doctrine. However, it is undisputable that such an agreement may be concluded by an agent. I mean here a power of attorney of the substantive law, and not the power to represent in the court proceedings.A principal may expressly authorize an agent to conclude a particular arbitration agreement (a specific power of attorney) or to conclude all arbitration agreements (a generic power of attorney).A question, however, arises, whether an agent aut
APA, Harvard, Vancouver, ISO, and other styles
36

Rahman, Md Motiur, Yasser Alatawi, Ning Cheng, et al. "Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS)." Clinical Drug Investigation 37, no. 12 (2017): 1143–52. http://dx.doi.org/10.1007/s40261-017-0574-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Lu, Thomas Y. "A survey of cases of the pay-for-delay agreement in the post-Actavis era." Queen Mary Journal of Intellectual Property 11, no. 1 (2021): 69–85. http://dx.doi.org/10.4337/qmjip.2021.01.04.

Full text
Abstract:
What are the further developments on pay-for-delay agreements following Actavis, the case decided by the US Supreme Court regarding a pay-for-delay dispute in 2013? We surveyed 17 pay-to-delay deals involving brand-name drug owners and generic companies to see how their deals were structured in light of Actavis, as well as the results of follow-on court cases involving such contracts. As a result, we posit here that a no-Authorized Generic (AG) provision, the clause in a pay-for-delay agreement that asks the company making the brand-name drug not to launch its own generic drug in the market, o
APA, Harvard, Vancouver, ISO, and other styles
38

Hilbe, Joseph M. "The Role of Statistics and Statisticians in the Future of Astrostatistics." Proceedings of the International Astronomical Union 10, S306 (2014): 400–406. http://dx.doi.org/10.1017/s1743921314013507.

Full text
Abstract:
AbstractGiven the generic definition of statistics, it is clear that astronomers have engaged in statistical analysis of some variety since astronomy first emerged as a science. However, from the early nineteenth century until the beginning of the twenty-first the two disciplines have been somewhat estranged – there was no formal relationship between the two. This has now changed, as is evidenced by the recent creation of the International Astrostatistics Association (IAA), the ISI astrostatistics committee, astrostatistics working groups authorized by the IAU and AAS, and this Symposium. The
APA, Harvard, Vancouver, ISO, and other styles
39

Uvarova, N. E., N. N. Eremenko, G. V. Ramenskaya, and D. V. Goryachev. "PLANNING AND EVALUATION OF BIOEQUIVALENCE STUDIES OF ATAZANAVIR PRODUCTS." Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 8, no. 3 (2018): 151–57. http://dx.doi.org/10.30895/1991-2919-2018-8-3-151-157.

Full text
Abstract:
The Government of the Russian Federation approved the State strategy of combating the spread of HIV aimed at prevention of HIV epidemic. One of the goals of the Strategy is to increase the coverage of antiretroviral therapy for people infected with HIV, which includes extensive use of generic drugs. In order for a generic drug to be authorised, the applicant has to submit a report on the results of the bioequivalence studies in which the generic product was compared to the reference product. Atazanavir is an antiretroviral drug, which is also the drug of choice for the treatment and prevention
APA, Harvard, Vancouver, ISO, and other styles
40

Maybarduk, Peter, and Sarah Rimmington. "Compulsory Licenses: A Tool to Improve Global Access to the HPV Vaccine?" American Journal of Law & Medicine 35, no. 2-3 (2009): 323–50. http://dx.doi.org/10.1177/009885880903500205.

Full text
Abstract:
AbstractCervical cancer disproportionately affects women in lower- and middle-income countries. But the new vaccines developed to prevent infection with some strains of the human papillomavirus (HPV) that cause cervical cancer are priced beyond the reach of most women and health agencies in these regions, due in part to the monopoly pricing power of brand-name companies that hold the patents on the vaccines. Compulsory licenses, which authorize generic competition with patented products, could expand access to HPV vaccines under certain circumstances. If high-quality biogeneric HPV vaccines ca
APA, Harvard, Vancouver, ISO, and other styles
41

Asnis, A. Ya. "Novels of the Criminal Code on responsibility for abusesin public procurement: background and problems of qualification". Russian competition law and economy, № 4 (30 грудня 2018): 34–43. http://dx.doi.org/10.32686/2542-0259-2018-4-34-43.

Full text
Abstract:
The article deals with the criminological grounds and background of the adoption of the Federal law of April 23, 2018 № 99-FZ, which introduced criminal liability for abuse in the procurement of goods, works and services for state or municipal needs (Art. 2004 of Criminal Code of the Russian Federation) and for bribery of employees of contract service, contract managers, members of the Commission on the implementation of the procurement of persons engaged in the acceptance of the delivered goods, performed works or rendered services, other authorized persons, representing interests of customer
APA, Harvard, Vancouver, ISO, and other styles
42

Šandor, Ksenija, Svjetlana Terzić, Anja Vujnović, Eleonora Perak Junaković, Irena Žarković, and Miroslav Andrišić. "Razvoj SPE-HPLC-DAD metode za određivanje florfenikola i florfenikol amina u cerebrospinalnoj tekućini svinja." Veterinarska stanica 51, no. 2 (2020): 129–38. http://dx.doi.org/10.46419/vs.51.2.3.

Full text
Abstract:
A study of florfenicol (FF) and its metabo- lite florfenicol amine (FFA) in pig cerebrospinal fluid was conducted following repeated intramuscular administration of the original (reference) and a generic veterinary medicinal product (VMP) under the same experimental conditions (20 mg FF/kg body weight, 48-hour interval). Both VMPs are solutions for injection containing FF as an active substance in the concentration of 300 mg/mL and have been authorized in Croatia for use in cattle and pigs. In this study, clinically healthy pigs were randomly divided into three groups. The first group was trea
APA, Harvard, Vancouver, ISO, and other styles
43

Deckers, Nynke, Catharina A. Ruigrok, Hans Peter Verhoeve, and Nicky Lourens. "Comparison of pain response after subcutaneous injection of two maropitant formulations to beagle dogs." Veterinary Record Open 5, no. 1 (2018): e000262. http://dx.doi.org/10.1136/vetreco-2017-000262.

Full text
Abstract:
The antiemetic maropitant, with metacresol as preservative (Cerenia, Zoetis), has been associated with pain after subcutaneous injection in dogs and cats. Recently, a generic formulation containing benzyl alcohol was authorised (Prevomax, Le Vet). Benzyl alcohol is reported to have local anaesthetic properties and reduce injection pain. This study compared local pain after subcutaneous injection of the two maropitant formulations, administered at approximately 4°C and 25°C, to dogs. Thirty-two healthy beagle dogs were enrolled into a blinded, randomised, cross-over study. Dogs received subcuta
APA, Harvard, Vancouver, ISO, and other styles
44

SOLOMONIDES, ANTHONY E., and TIM KEN MACKEY. "Emerging Ethical Issues in Digital Health Information." Cambridge Quarterly of Healthcare Ethics 24, no. 3 (2015): 311–22. http://dx.doi.org/10.1017/s0963180114000632.

Full text
Abstract:
Abstract:The problems of poor or biased information and of misleading health and well-being advice on the Internet have been extensively documented. The recent decision by the Internet Corporation for Assigned Names and Numbers to authorize a large number of new generic, top-level domains, including some with a clear connection to health or healthcare, presents an opportunity to bring some order to this chaotic situation. In the case of the most general of these domains, “.health,” experts advance a compelling argument in favor of some degree of content oversight and control. On the opposing s
APA, Harvard, Vancouver, ISO, and other styles
45

Drąg, Paweł, and Mateusz Szymura. "TECHNICAL AND LEGAL ASPECTS OF DATABASE'S SECURITY IN THE LIGHT OF IMPLEMENTATION OF GENERAL DATA PROTECTION REGULATION." CBU International Conference Proceedings 6 (September 25, 2018): 1056–61. http://dx.doi.org/10.12955/cbup.v6.1294.

Full text
Abstract:
In the modern era, information is not only a valuable commodity, but also a potential source of threat, especially when it comes to personal data. The implementation of the General Data Protection Regulation seeks to unify regulations and safeguards in a same manner across the EU. The following paper surveys how the legal aspects of GDPR influence the existing technical framework of databases containing personal data. In this research we want to show if the already existing technical infrastructure and safeguards implemented in databases containing personal data are sufficient and if not, if i
APA, Harvard, Vancouver, ISO, and other styles
46

Youssef, Tarek A., Mohammad Mahmoudian Esfahani, and Osama Mohammed. "Data-Centric Communication Framework for Multicast IEC 61850 Routable GOOSE Messages over the WAN in Modern Power Systems." Applied Sciences 10, no. 3 (2020): 848. http://dx.doi.org/10.3390/app10030848.

Full text
Abstract:
In this paper, a data-centric communication framework is proposed for multicast routable generic object-oriented substation event (GOOSE) messages (MRGM) over the wide area network (WAN) for effective substation-to-substation (SS2SS) and substation to control center (SS2CC) communications. In this structure, the IEC 61850 GOOSE message is transmitted over the WAN using the data distribution service (DDS) as a fast, reliable, and secure data-centric communication middleware. The main feature of this framework is its multicast capability, where several authorized subscribers can receive a publis
APA, Harvard, Vancouver, ISO, and other styles
47

Milchior, Richard. "Impact of Court Cases on Summary of Product Characteristics Harmonisation." Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 2, no. 3 (2005): 240–51. http://dx.doi.org/10.1057/palgrave.jgm.4940075.

Full text
Abstract:
This paper deals with the evolution of European Court of Justice (ECJ) case law. The ECJ had to decide in the Artedogan case whether the national authorities or the Commission should be able to modify marketing authorisation granted at the national level. The ECJ decided that in the situation where the marketing authorisation was of national origin, a modification could not be decided on by the European Commission on the basis of the then article 15a of directive 75/189 (today article 36 of directive 2001/83). The debate has now shifted, and the new issue is to decide who is authorised to forc
APA, Harvard, Vancouver, ISO, and other styles
48

HERINEAN, Dorel. "Cauzele justificative și transmiterea unor boli infectocontagioase." Analele Universitării din București Drept 2020, no. 2020 (2020): 319–47. http://dx.doi.org/10.31178/aubd.2020.17.

Full text
Abstract:
In the context of the COVID-19 pandemic, this article analyses some possibilities provided by the law in order to protect the public health or the health of an individual, respectively the commission of certain actions sanctioned by the criminal law under the incidence of the justification causes, with the consequence of their lack of criminal character. Whether it is the means of retaliation or rescue that can be used by a person facing the transmission of infectious diseases, the actions necessary to prevent or combat the pandemic that the law authorizes or the availability or not of a perso
APA, Harvard, Vancouver, ISO, and other styles
49

Mrvic-Petrovic, Natasa, and Zdravko Petrovic. "State responsibility for damage caused by unfair sentence or unfounded arrest." Zbornik Matice srpske za drustvene nauke, no. 145 (2013): 653–65. http://dx.doi.org/10.2298/zmsdn1345653m.

Full text
Abstract:
The legal basis of state responsibility for damage caused by unfair sentence or unfounded arrest is the need to protect fundamental human rights and freedoms guaranteed by the Constitution and generally accepted international rules. The right to compensation on this basis (although subjective civil right) has a sui generis legal nature, because it is connected with the protection of human rights. Joint public-private legal nature of such a request is expressed in the legislation of the Republic of Serbia, because the circle of authorized persons and the conditions under which they may be entit
APA, Harvard, Vancouver, ISO, and other styles
50

Mastralexi, Aspasia, and Maria Z. Tsimidou. "The Potential of Virgin Olive Oil from cv. Chondrolia Chalkidikis and Chalkidiki (Greece) to Bear Health Claims according to the European Legislation." Molecules 26, no. 11 (2021): 3184. http://dx.doi.org/10.3390/molecules26113184.

Full text
Abstract:
The European food legislation authorizes the use of certain health claims based on a scientific basis. This study aimed to evaluate the fatty acid, tocopherol, and polar phenol composition of virgin olive oil (VOO) from cv. Chondrolia Chalkidikis and Chalkidiki regarding the fulfillment of official requirements for the health claims of ‘oleic acid’, ‘vitamin E’, and ‘olive oil polyphenols’. The examination of representative industrial VOOs from 15 olive mills of the Chalkidiki regional unit showed that the two cultivars yield oils contained the necessary concentrations of the responsible bioac
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography